This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.
Article Attribution | Read More at Article Source
The post This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho appeared first on RocketNews.